Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure

Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.

BACKGROUND Persistent inflammation appears to play a role in the development of heart failure (HF). Osteoprotegerin (OPG), the receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) are newly discovered members of the tumor necrosis factor superfamily that are critical regulators in bone metabolism but appear also to be involved in immune responses. We hypothesized that the...

Experimental Heart Failure

(pacing-induced) dogs. The sensitivity of these units was compared between the two groups of dogs. After development of clinical heart failure, the animals were anesthetized, and the left carotid sinus was vascularly isolated and perfused with oxygenated Krebs-Henseleit solution. Single-unit baroreceptor discharge was recorded from the carotid sinus nerve in response to stepwise increases in ca...

Clinical Challenges in Heart Failure

Carefully weighing the risks and benefits of specific therapies, the ensuing discourse presents a fair, balanced approach to conceptual controversies as well as exploring the diagnostic and therapeutic dilemmas that may arise. Recent and ongoing trials are discussed, as well as the potential impact on clinical practice of emerging therapies. This book is designed for the busy clinical practitio...

Clinical Challenges in Heart Failure

Carefully weighing the risks and benefits of specific therapies, the ensuing discourse presents a fair, balanced approach to conceptual controversies as well as exploring the diagnostic and therapeutic dilemmas that may arise. Recent and ongoing trials are discussed, as well as the potential impact on clinical practice of emerging therapies. This book is designed for the busy clinical practitio...

Experimental Models of Heart Failure